ATE518867T1 - Benzothienoä2,3-düpyrimidin-verindungen als inhibitoren der aktivität der tyrosinkinase epidermaler wachstumsfaktorrezeptoren zur behandlung hyperproliferativer krankheiten - Google Patents

Benzothienoä2,3-düpyrimidin-verindungen als inhibitoren der aktivität der tyrosinkinase epidermaler wachstumsfaktorrezeptoren zur behandlung hyperproliferativer krankheiten

Info

Publication number
ATE518867T1
ATE518867T1 AT05815411T AT05815411T ATE518867T1 AT E518867 T1 ATE518867 T1 AT E518867T1 AT 05815411 T AT05815411 T AT 05815411T AT 05815411 T AT05815411 T AT 05815411T AT E518867 T1 ATE518867 T1 AT E518867T1
Authority
AT
Austria
Prior art keywords
düpyrimidine
tyrosinkinase
inhibitors
activity
compounds
Prior art date
Application number
AT05815411T
Other languages
English (en)
Inventor
Chengzhi Zhang
Roger Smith
Jason Duquette
Qian Zhao
Jacques Dumas
Georgiy Bondar
Yingfu Li
Dongping Fan
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE518867T1 publication Critical patent/ATE518867T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05815411T 2004-10-15 2005-10-14 Benzothienoä2,3-düpyrimidin-verindungen als inhibitoren der aktivität der tyrosinkinase epidermaler wachstumsfaktorrezeptoren zur behandlung hyperproliferativer krankheiten ATE518867T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61906604P 2004-10-15 2004-10-15
PCT/US2005/036791 WO2006044524A1 (en) 2004-10-15 2005-10-14 Benzothieno’2,3-d! pyrimidine compounds as inhibitors of tyrosine kinase activities of the epidermal growth factor receptors (egfrs) for the treatment of hyperproliferative diseases

Publications (1)

Publication Number Publication Date
ATE518867T1 true ATE518867T1 (de) 2011-08-15

Family

ID=35759133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05815411T ATE518867T1 (de) 2004-10-15 2005-10-14 Benzothienoä2,3-düpyrimidin-verindungen als inhibitoren der aktivität der tyrosinkinase epidermaler wachstumsfaktorrezeptoren zur behandlung hyperproliferativer krankheiten

Country Status (12)

Country Link
US (1) US7750017B2 (de)
EP (1) EP1802633B1 (de)
JP (1) JP5070058B2 (de)
AR (1) AR052019A1 (de)
AT (1) ATE518867T1 (de)
CA (1) CA2584303A1 (de)
ES (1) ES2369235T3 (de)
GT (1) GT200500291A (de)
PE (1) PE20060976A1 (de)
TW (1) TW200628473A (de)
UY (1) UY29161A1 (de)
WO (1) WO2006044524A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
US8802849B2 (en) 2008-02-19 2014-08-12 Vichem Chemie Kutató Kft. Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use
AP2975A (en) 2008-07-16 2014-09-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
HK1210696A1 (en) * 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US20160159816A1 (en) * 2013-02-01 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof
TW201605867A (zh) * 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231173B1 (hu) 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
WO2019126443A1 (en) 2017-12-21 2019-06-27 Ribon Therapeutics Inc. Quinazolinones as parp14 inhibitors
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
CN108456184B (zh) * 2018-03-28 2020-02-07 南方医科大学 一种靶向egfr与eps8结合的小分子抑制剂及其应用
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
CN110818618A (zh) * 2019-11-26 2020-02-21 山东铂源药业有限公司 一种吡咯替尼中间体2-[(2-氯-4-硝基苯氧基)甲基]吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
SK284073B6 (sk) * 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze

Also Published As

Publication number Publication date
UY29161A1 (es) 2006-04-28
EP1802633A1 (de) 2007-07-04
PE20060976A1 (es) 2006-10-20
AR052019A1 (es) 2007-02-28
EP1802633B1 (de) 2011-08-03
US20080132497A1 (en) 2008-06-05
TW200628473A (en) 2006-08-16
ES2369235T3 (es) 2011-11-28
CA2584303A1 (en) 2006-04-27
US7750017B2 (en) 2010-07-06
JP5070058B2 (ja) 2012-11-07
GT200500291A (es) 2006-10-10
JP2008516963A (ja) 2008-05-22
WO2006044524A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
EP2117523A4 (de) Hemmer von akt-aktivität
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE453635T1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EP2303269A4 (de) Hemmer der akt-aktivität
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EP2299825A4 (de) Hemmer der akt-aktivität
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602007011906D1 (de) Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ATE518867T1 (de) Benzothienoä2,3-düpyrimidin-verindungen als inhibitoren der aktivität der tyrosinkinase epidermaler wachstumsfaktorrezeptoren zur behandlung hyperproliferativer krankheiten
EP2120951A4 (de) Hemmer der akt-aktivität
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602007009877D1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties